FOLH1 and cancer: In vitro, these anti‐PSMA LNPs demonstrated enhanced uptake and transfection in PSMA+ cancer cells, such as B16‐F10‐PSMA (Figure 3A,B) and LNCaP (Figure S3, Supporting Information), compared to nontargeted LNPs and PSMA− cells (B16‐F10 and DU145).